Novel family of 5HT2B-selective antagonists for neuropathologies, such as Alzheimer’s disease, depression, ADHD, and migraines. Potential application in cardiology, gastroenterology, and bone marrow diseases.

Serotonin receptors are popular targets for many diseases, particularly neuropathologies. The existence of 14 subtypes, however, necessitates selective ligands. Current drugs tend to bind non-selectively to 5-HT2A and 5-HT2C as well as 5-HT2B, limiting their use. The proposed antagonists offer increased selectivity to 5-HT2B. These compounds exhibit nanomolar to micromolar selective interactions, which increases efficacy and reduces side effects of therapeutics. 5HT2B has additional potential applications in gastrointestinal, cardiac, and bone marrow related conditions.